Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCHR1 | Q99705 | 19/20 | 0.73 |
| ▸ | HTR2C | P28335 | 1/20 | 0.73 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6920225 | 0.90 | MCHR1 (0.70) | MCHR1HTR2C | |
| SCHEMBL6923778 | 0.88 | MCHR1 (0.78) | MCHR1HTR2CSLC2A1 | |
| SCHEMBL6926340 | 0.88 | MCHR1 (0.92) | MCHR1HTR2CSLC2A1 | |
| SCHEMBL6924942 | 0.87 | MCHR1 (0.75) | MCHR1HTR2CSLC2A1 | |
| SCHEMBL6602562 | 0.87 | MCHR1 (0.75) | MCHR1HTR2CSLC2A1 | |
| SCHEMBL6572159 | 0.86 | MCHR1 (0.74) | MCHR1HTR2CSLC2A1 | |
| SCHEMBL6569338 | 0.86 | MCHR1 (0.74) | MCHR1HTR2CSLC2A1 | |
| SCHEMBL6917438 | 0.85 | MCHR1 (0.70) | MCHR1HTR2CSLC2A1 | |
| SCHEMBL6926161 | 0.85 | MCHR1 (0.76) | MCHR1HTR2C | |
| SCHEMBL6926509 | 0.84 | MCHR1 (1.00) | MCHR1HTR2CSLC2A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1001766-B1 | COMPOUNDS FOR THE TREATMENT OF CCR5-MEDIATED DISEASES | SMITHKLINE BEECHAM CORP (US) | 2003-04-09 | — | — | EP | claimed |
| US-6515027-B1 | Ligands, agonists or antagonists, of the CC chemokine receptor CC-CKR5 | SMITHKLINE BEECHAM CORP. | 2003-02-04 | — | — | US | claimed |
| EP-4143235-A1 | METHODS AND COMPOSITIONS FOR TREATING CYTOKINE STORM INFECTIONS, INCLUDING COVID-19, BY INHIBITING CCR5/CCL5 INTERACTION | IncellDx, Inc. (US) | 2023-03-08 | — | — | EP | disclosed |
| WO-2021222069-A1 | METHODS AND COMPOSITIONS FOR TREATING CYTOKINE STORM INFECTIONS, INCLUDING COVID-19, BY INHIBITING CCR5/CCL5 INTERACTION | INCELLDX, INC. (US) | 2021-11-04 | — | — | WO | disclosed |
| EP-1001766-B1 | COMPOUNDS FOR THE TREATMENT OF CCR5-MEDIATED DISEASES | SMITHKLINE BEECHAM CORP (US) | 2003-04-09 | — | — | EP | disclosed |
| US-6515027-B1 | Ligands, agonists or antagonists, of the CC chemokine receptor CC-CKR5 | SMITHKLINE BEECHAM CORP. | 2003-02-04 | — | — | US | disclosed |